BMY Related Earnings News
-
Merck (MRK) Immuno-Oncology Offering Lacks Combo; Goldman Maintains Neutral
-
Bristol-Myers Squibb (BMY) Immuno-Oncology 'Paradigm Changing' - Goldman
-
UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
-
Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
-
Bristol-Myers Squibb Co. (BMY) Reports In-Line Q1 EPS; Reaffirms
-
ICON (ICLR) on Watch as Bristol-Myers Squibb (BMY) Adds New Lab Provider
-
Bristol-Myers (BMY) Tops Q4 EPS by 5c; Issues In-Line FY13 EPS Outlook
-
The Medicines Co (MDCO) and Bristol-Myers Squibb (BMY) Enter Collaboration on Recothrom
-
Bristol-Myers Squibb Co. (BMY) Misses Q3 EPS by 1c; Sees EPS at High End
-
NACF Conference Could Create Catalyst for Vertex (VRTX) - Analyst
-
UBS Reiterates a 'Buy' on Gilead Sciences (GILD); Raises Numbers on Favorite Large-Cap Biotech
-
Bristol-Myers Squibb (BMY) to Take $1.8B Non-Cash Charge on Hep C Development Halt
-
Barclays Lowers Outlook on Idenix Pharmaceuticals (IDIX); Clarity on FDA Clinical Hold (BMY, VRTX, GILD)
-
Buy Bristol-Myers (BMY) On Weakness - Jefferies
-
Nomura Securities Reiterates a 'Reduce' on AstraZeneca (AZN); Overpayment Risk in Deal with Bristol Myers (BMY)
-
Bristol-Myers Squibb Co. (BMY) Misses Q2 EPS by 1c
-
Bristol-Myers Squibb Co. (BMY) Tops Q1 EPS by 1c; Sales Light
-
Q4 Preview: Pfizer (PFE) May Suffer Same Ailment as Peers: Strong Dollar Syndrome
-
Bristol-Myers Squibb Co. (BMY) Misses Q4 EPS by 2c, Sales Fall Just Short
-
Bristol-Myers Squibb Co. (BMY) Tops Q3 EPS by 3c; Narrows FY11 Guidance
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 1c; Raises FY11 Outlook
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 5c; Reaffirms Outlook
-
Bristol-Myers Squibb (BMY) Reports Q4 Adj-EPS of 47c, Misses by 1c; Guides FY11 Below the Street
-
Bristol-Myers (BMY) Reports Mixed Q3 Results; Affirms FY10 Guidance
-
Bristol-Myers (BMY) Q2 Profits Drop, But Match Street Views
-
Bristol-Myers (BMY) Reports Inline Q2 EPS of $0.53
-
Bristol-Myers (BMY) Tops Q1 Views But Lowers FY10 EPS Outlook
-
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c; Guides
-
Bristol-Myers (BMY) Updates FY09 GAAP, Non-GAAP EPS Guidance
-
Exelixis (EXEL) Tops Q3 EPS by 8c; Comments on Outlook
-
Bristol Myers Squibb (BMY) Reports Q3 EPS of $0.52
-
Bristol-Myers (BMY) Tops Street's EPS View by 9c; Raises FY09 Outlook
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 1c
-
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Lifts Lower End of '08 EPS Views
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Guides
-
Bristol-Myers Squibb (BMY) Reaffirms 2008 Earnings Guidance
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 1c, Reaffirms Forecast; Plans IPO for Mead Johnson Nutritionals
-
Bristol-Myers Squibb (BMY) Misses Q4 EPS by 1c
-
Bristol-Myers Squibb (BMY) Announces Review Including Headcount Reductions; Guides, Raises Dividend
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 1c
-
Bristol-Myers Squibb (BMY) to Reaffirm FY07-08 Financial Guidance
-
Bristol-Myers Squibb (BMY) Reports Q2 Earnings, Raises FY07 EPS and Guides for FY08
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 15c; Guides Higher
-
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 3c; Guides
-
Bristol-Myers Squibb (BMY) Announces Settlement of Federal Investigation, Guides Lower for FY GAAP EPS
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 2c; Guides Above
-
Bristol-Myers Squibb (BMY) Lowers FY EPS Guidance on Generic PLAVIX Already on Market
-
sanofi-aventis (SNY) Cuts 2006 EPS Growth Target On Already Shipped Generic Plavix
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Reaffirms
Back to BMY Stock Lookup
